tetano
Editor, Senior Moderator
Inform Med Unlocked
. 2021;25:100675.
doi: 10.1016/j.imu.2021.100675. Epub 2021 Jul 27.
Emerging mutations in envelope protein of SARS-CoV-2 and their effect on thermodynamic properties
Kejie Mou[SUP] 1 [/SUP], Mohnad Abdalla[SUP] 2 [/SUP], Dong Qing Wei[SUP] 3 4 [/SUP], Muhammad Tahir Khan[SUP] 5 [/SUP], Madeeha Shahzad Lodhi[SUP] 5 [/SUP], Doaa B Darwish[SUP] 6 [/SUP], Mohamed Sharaf[SUP] 7 8 [/SUP], Xudong Tu[SUP] 9 [/SUP]
Affiliations
Abstract
Structural proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are potential drug targets due to their role in the virus life cycle. The envelope (E) protein is one of the structural proteins; plays a critical role in virulency. However, the emergence of mutations oftenly leads to drug resistance and may also play a vital role in virus stabilization and evolution. In this study, we aimed to identify mutations in E proteins that affect the protein stability. About 0.3 million complete whole genome sequences were analyzed to screen mutations in E protein. All these mutations were subjected to stability prediction using the DynaMut server. The most common mutations that were detected at the C-terminal domain, Ser68Phe, Pro71Ser, and Leu73Phe, were examined through molecular dynamics (MD) simulations for a 100ns period. The sequence analysis shows the existence of 259 mutations in E protein. Interestingly, 16 of them were detected in the DFLV amino acid (aa) motif (aa72-aa75) that binds the host PALS1 protein. The results of root mean square deviation, fluctuations, radius of gyration, and free energy landscape show that Ser68Phe, Pro71Ser, and Leu73Phe are exhibiting a more stabilizing effect. However, a more comprehensive experimental study may be required to see the effect on virus pathogenicity. Potential antiviral drugs, and vaccines may be developed used after screening the genomic variations for better management of SARS-CoV-2 infections.
Keywords: Antiviral drugs; Envelope; Genome; Mutations; SARS-CoV-2; Stability.
. 2021;25:100675.
doi: 10.1016/j.imu.2021.100675. Epub 2021 Jul 27.
Emerging mutations in envelope protein of SARS-CoV-2 and their effect on thermodynamic properties
Kejie Mou[SUP] 1 [/SUP], Mohnad Abdalla[SUP] 2 [/SUP], Dong Qing Wei[SUP] 3 4 [/SUP], Muhammad Tahir Khan[SUP] 5 [/SUP], Madeeha Shahzad Lodhi[SUP] 5 [/SUP], Doaa B Darwish[SUP] 6 [/SUP], Mohamed Sharaf[SUP] 7 8 [/SUP], Xudong Tu[SUP] 9 [/SUP]
Affiliations
- PMID: 34337139
- PMCID: PMC8314890
- DOI: 10.1016/j.imu.2021.100675
Abstract
Structural proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are potential drug targets due to their role in the virus life cycle. The envelope (E) protein is one of the structural proteins; plays a critical role in virulency. However, the emergence of mutations oftenly leads to drug resistance and may also play a vital role in virus stabilization and evolution. In this study, we aimed to identify mutations in E proteins that affect the protein stability. About 0.3 million complete whole genome sequences were analyzed to screen mutations in E protein. All these mutations were subjected to stability prediction using the DynaMut server. The most common mutations that were detected at the C-terminal domain, Ser68Phe, Pro71Ser, and Leu73Phe, were examined through molecular dynamics (MD) simulations for a 100ns period. The sequence analysis shows the existence of 259 mutations in E protein. Interestingly, 16 of them were detected in the DFLV amino acid (aa) motif (aa72-aa75) that binds the host PALS1 protein. The results of root mean square deviation, fluctuations, radius of gyration, and free energy landscape show that Ser68Phe, Pro71Ser, and Leu73Phe are exhibiting a more stabilizing effect. However, a more comprehensive experimental study may be required to see the effect on virus pathogenicity. Potential antiviral drugs, and vaccines may be developed used after screening the genomic variations for better management of SARS-CoV-2 infections.
Keywords: Antiviral drugs; Envelope; Genome; Mutations; SARS-CoV-2; Stability.